Nov 15, 2021
In this “Ask Me Anything” (AMA)
episode, Peter and Bob discuss all things related to GLP-1
agonists—a class of drugs that are gaining popularity for the
treatment of obesity. They cover the discovery of these peptides,
their physiology, and what it is they do in their natural state.
Next, Peter and Bob break down a recently published study which
showed remarkable results for weight loss and other metabolic
parameters using a once-weekly injection of the GLP-1 agonist drug
semaglutide, also known as Ozempic, in overweight and obese
patients. Finally, they compare results from the semaglutide study
to results from various lifestyle interventions and give their take
on the potential future of GLP-1 agonists.
If you’re not a subscriber and listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or on our website at the AMA #29 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.